amoxicillin / Generic mfg. - LARVOL DELTA

Synergistic potentiation of antibiotics by chamomile phytochemicals against multidrug-resistant Helicobacter pylori. (PubMed, Gut Pathog) - "Chamomile ethanolic extract shows promising anti-H. pylori activity and can enhance the effectiveness of standard antibiotics, indicating its potential as a complementary treatment to combat antibiotic-resistant H. pylori infections."

Journal • Infectious Disease

Implementation of a Pharmacist-Led Penicillin Allergy History Algorithm with the Direct Oral Amoxicillin Challenge in Hospitalized Patients (ASHP 2025) - No abstract available

Clinical • Allergy • Immunology

Utilization of Amoxicillin Oral Challenge Protocol in a Community Hospital Emergency Department (ASHP 2025) - No abstract available

Clinical

Evaluation of Amoxicillin Challenge Use in Adult Patients with a Reported Penicillin Allergy (ASHP 2025) - No abstract available

Clinical • Allergy • Immunology

Inpatient Oral Amoxicillin Challenges for Pediatric Patients with Qualifying Low Risk Penicillin Allergies (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Clinical • Allergy • Immunology • Pediatrics

Amide-functionalized cellulose derived from sugarcane bagasse for efficient removal of amoxicillin and moxifloxacin from water. (PubMed, Int J Biol Macromol) - "The maximum adsorption capacities (qmax) obtained under optimized experimental condition were 473.46 mg/g and 435.38 mg/g for AMX and MOX respectively. Owing to low cost and high efficiency, amide functionalized cellulose obtained from sugarcane bagasse could be used as an alternative adsorbent to expensive commercial adsorbents for the removal of antibiotics and other pollutants from water."

Journal

Tailoring Nanoparticle Surfaces Empowered by Multivariate Techniques for Detection of Multiple Antibiotic Fingerprints in Real Samples Using Hand-Held Colorimetric Signal Readout. (PubMed, ACS Appl Mater Interfaces) - "With 100% accuracy, the sensor array successfully discriminates between eight antibiotics (amoxicillin, azithromycin, neomycin, streptomycin, chloramphenicol, ofloxacin, fluconazole, and ciprofloxacin), with detection limits ranging from 1.7 to 8.3 μM. Further, for the real-time applications, we have developed prototypes for colorimetric analysis and also modified the previously developed 96-well plate reader, which functions similarly to the UV-visible absorption spectrophotometer. These on-site sensing methods, with straightforward preparation, quick response, exceptional sensitivity, and consistently stable high-throughput signal output, show significant potential for practical use in food forensics and for environmental remediation."

Journal

Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the Clinical Practice Research Datalink (CPRD). (PubMed, Pharmacoepidemiol Drug Saf) - "Using a carefully designed reference set of drug-outcome pairs well suited to the study design, the SCCS performed moderately well for signal detection in CPRD. Whilst active comparators effectively reduced confounding by indication, they also reduced the number of correctly identified positive controls, due to a reduction in power. We showed some evidence that SCCS is able to highlight SDRs before they were present on labels."

Journal

Antibacterial activity of Cerium Oxide Nanoparticles: a systematic review and meta-analysis study. (PubMed, Nanomedicine (Lond)) - "Compared to conventional antibiotics, CeO2 NPs were generally less effective (SMD = -2.846, p < 0.0001) but performed comparably to Amoxicillin, Streptomycin, Linezolid, and Clindamycin. CeO2 NPs demonstrate significant broad-spectrum antibacterial activity, suggesting potential against antibiotic-resistant bacteria. Future research should explore synergistic effects with standard antibiotics."

Journal • Retrospective data • Review • Infectious Disease

Toxic Epidermal Necrolysis Induced by First-Line Helicobacter pylori Eradication Therapy: A Case Report. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "Here, we report a fatal case of TEN in an 80-year-old patient who developed diffuse bullous eruptions and multiorgan failure following first-line Helicobacter pylori eradication therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Despite intensive care, including corticosteroids and supportive treatment, the patient died of sepsis and progressive organ failure. This case highlights the need for early detection of severe cutaneous adverse reactions, particularly in elderly patients receiving H. pylori eradication therapy."

Journal • Critical care • Infectious Disease • Septic Shock • Steven-Johnson Syndrome

Docosahexaenoic Acid-Driven Metabolic Reprogramming as an Attractive Anti-Infection Strategy to Potentiate β-Lactam Antibiotic Efficacy. (PubMed, Research (Wash D C)) - "Furthermore, to enhance the pharmacodynamic performance and stability of DHA, amoxicillin and DHA co-loaded nanoemulsions (Amo/DHA-NEs) were prepared via high-energy emulsification. Intriguingly, we found that Amo/DHA-NEs effectively rescued MRSA-induced infections in the murine infection models, as evidenced by the superior bacterial clearance and mitigated inflammation. Collectively, this work reveals a potentially exploitable link between DHA-driven metabolic reprogramming and β-lactams resistance, and we propose combination therapies of DHA and β-lactams targeting the emerging threat of MRSA infections."

Journal • Infectious Disease • Inflammation • Metabolic Disorders

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. (PubMed, J Antimicrob Chemother) - "Sulbactam/durlobactam significantly increased susceptibility to oral and intravenous β-lactam antibiotics in the form of cefuroxime, cefuroxime/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to β-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the β-lactam combinations studied could result in clinical efficacy for M. abscessus disease."

Journal • Preclinical

Determination of antimicrobial resistance pattern among post-operative orthopedic implant patients in a tertiary care hospital: A retrospective study. (PubMed, Int J Clin Pharmacol Ther) - "The critical challenges of antimicrobial resistance in orthopedic implant-related infections have been highlighted. Urgent institutional and policy level interventions are required for implementation of stringent infection control protocols and robust antibiotic stewardship programs to prevent a post-antibiotic crisis."

Journal • Retrospective data • Infectious Disease • Orthopedics

Nanocurcumin: An Innovative Strategy to Combat Virulence and Methicillin Resistance in Staphylococcus aureus Isolated from Burn Wounds. (PubMed, Iran J Med Sci) - "The 50 selected isolates were resistant to cefoxitin, amoxicillin, benzylpenicillin, ampicillin/sulbactam, piperacillin/tazobactam, cloxacillin, oxacillin, and azithromycin. No significant changes were seen in fnbA and ftsZ. Nanocurcumin inhibits S. aureus virulence and resistance genes, reducing biofilm formation and toxin production, but lacks effect on fnbA and ftsZ, requiring further research."

Journal • Infectious Disease

Procedural Challenges in Soil Sample Preparation for Pharmaceuticals Analysis. (PubMed, Molecules) - "Our results indicate that some compounds can be eliminated even up to 100% (including amoxicillin, ampicillin, and lincomycin) during ultrasonication and/or filtration. This study demonstrates that even problematic compounds, despite their low recovery, can be analyzed by the addition of isotopically labelled internal standards with acceptable accuracy. This finding is particularly important for environmental monitoring, where trace-level detection of pharmaceutical residues is often challenged by matrix complexity and analyte instability."

Journal

Patient with Inflammatory Bowel Disease in a Dental Office-Which Antibiotic to Choose?-Narrative Review. (PubMed, J Clin Med) - " The available evidence suggests that first- and second-line dental antibiotics-amoxicillin, ampicillin, and clindamycin-carry the highest risk of CDI. Tailored, microbiome-conscious antibiotic strategies are essential in dental management of IBD patients. Further clinical research is needed to develop evidence-based guidelines and validate promising adjunctive approaches."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

PRO-EXOD: Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases (clinicaltrials.gov) - P4 | N=352 | Not yet recruiting | Sponsor: University of Sao Paulo General Hospital

New P4 trial • Immunology • Infectious Disease • Rheumatology

Increasing the pneumonia treatment coverage among children under 5 years old through 'Enhanced Management of Pneumonia in the Community': implementation research protocol. (PubMed, BMJ Open) - "The current implementation research using both qualitative and quantitative data collection methods will assess the feasibility and acceptability of iCCM-trained HSAs managing chest indrawing pneumonia and fast-breathing pneumonia in children under 5 with oral amoxicillin at the community level in district Kasungu using the existing district health system...Ethical approval was obtained from the National Health Research Sciences Committee and the WHO Ethics Committee. The implementation research findings will be disseminated to national-level stakeholders and specifically targeted at District Health Offices, which are responsible for implementing the interventions."

Journal • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases

Fourteen-and Ten-Day Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication-A Noninferiority, Multicenter, Randomized Controlled Trial. (PubMed, J Gastroenterol Hepatol) - "The eradication rate of the 14-THA group is > 90%, which is not inferior to the current bismuth-containing quadruple regimen, with a favorable safety profile. However, the efficacy of the 10-THA dual therapy is unacceptable."

Head-to-Head • Journal • Infectious Disease

Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population. (PubMed, Helicobacter) - "Empiric bismuth quadruple therapy had the highest eradication rate while metronidazole and levofloxacin triple therapies had the lowest. Eradication rates may thus serve as a surrogate clinical endpoint when choosing empiric therapies."

Journal • Retrospective data • Infectious Disease

Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial. (PubMed, Lancet Reg Health Am) - P4 | "We compared optimized bismuth quadruple therapy: esomeprazole 40 mg three times a day, amoxicillin 1 gr three times a day, metronidazole 500 mg three times a day, and bismuth subsalicylate 369 mg three times a day for 14 days, and standard triple therapy omeprazole 20 mg twice a day, amoxicillin 1 gr twice a day, and clarithromycin 500 mg twice a day for 14 days in a Chilean population. Optimized bismuth quadruple therapy is a reliable and safe empiric eradication therapy, especially in areas with high clarithromycin resistance. FONDECYT (1230504 AR); ANID-FONDAP (152220002 AR); Horizon 2020 program of European Union (825832 AR); ANID-FONDAP (15130011)."

Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor • CYP2C19

Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori (clinicaltrials.gov) - P3 | N=461 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Apr 2025 | Trial primary completion date: Jan 2026 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

NextGen - Clinical Implication of Next Generation Sequencing (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2028

Biomarker • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Novel drug-loaded nano-polymer comparison: amoxicillin between ceftriaxone for MCF-7 breast cancer cytotoxicity. (PubMed, J Biomater Sci Polym Ed) - "This work establishes a scalable nano-polymer platform for antibiotic repurpose, identifies ceftriaxone as a superior candidate for breast cancer therapy, and provides a critical mechanistic bridge between drug chemistry and tumor biology. With its established clinical safety, this ceftriaxone-based system represents a viable candidate for rapid translation to in vivo studies."

Journal • Breast Cancer • Oncology • Solid Tumor

Targeted LC-MS/MS method for quantifying respiratory pharmaceuticals in wastewater. (PubMed, Environ Sci (Camb)) - "Application to 12 neighborhood-level wastewater samples detected 9 of the 10 target compounds, with 6 (albuterol, amoxicillin, azithromycin, cetirizine, diphenhydramine, and fexofenadine), detected above their quantification limits. Fexofenadine was the most abundant, reaching 3309 ng L-1. This robust, low-volume, high-throughput LC-MS/MS method enables the reliable detection of respiratory pharmaceuticals in wastewater, supporting WBE applications for pharmaceutical use surveillance."

Journal • Respiratory Diseases